ARS Pharmaceuticals, Inc. SPRY
4.08 USD +0.51 (+14.24%)
Nov 11, 2026, 10:51 AM EST
3.57 Day range 4.13
2.44 52-week range 13.15
- YTD
- -64.99%
- 1 year
- -53.50%
News
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
defenseworld.net CenterBook Partners LP Buys 295,532 Shares of ARS Pharmaceuticals, Inc. $SPRY CenterBook Partners LP raised its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 239.1% in the third quarter, according to the company in its most recent filing with the Securities…
benzinga.com ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results ARS Pharmaceuticals (NASDAQ:SPRY) on Thursday reported weaker-than-expected results for the third quarter.
benzinga.com ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results ARS Pharma missed Q3 earnings and sales estimates; shares rose 5.6% premarket as analysts cut price targets despite neffy progress.
seekingalpha.com ARS Pharmaceuticals, Inc. (SPRY) Q3 2026 Earnings Call Transcript ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Donn Casale - CEO, President & Director Meg Smith Kathleen Scott - Chief Financial Officer…
benzinga.com Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Lowers Price Target to $20 Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and lowers the price target from $30 to $20.
benzinga.com Raymond James Downgrades ARS Pharmaceuticals to Outperform, Lowers Price Target to $17 Raymond James analyst Ryan Deschner downgrades ARS Pharmaceuticals (NASDAQ:SPRY) from Strong Buy to Outperform and lowers the price target from $28 to $17.
marketbeat.com ARS Pharmaceuticals Q3 Earnings Call Highlights ARS Pharmaceuticals NASDAQ: SPRY reported $33.4 million in third-quarter U.S. net product revenue from its needle-free epinephrine treatment neffy and reaffirmed its goal of reaching cash flow…
zacks.com ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.52 per share a year ago.
benzinga.com ARS Pharmaceuticals Q3 2026 Earnings Call Transcript ARS Pharmaceuticals (NASDAQ:SPRY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com ARS Pharmaceuticals Q3 EPS $(0.36) Misses $(0.31) Estimate, Sales $37.710M Miss $41.992M Estimate ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 30.77 percent increase over losses…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Biomea Fusion (NASDAQ:BMEA) stock increased by 11.0% to $1.51 during Monday's after-market session. The market value of their outstanding shares is at $102.9 million. iTonic Holdings…
benzinga.com Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures mixed, Dow down 0.1%. Swarmer Inc (NASDAQ: SWMR) shares drop 7% after reporting worse-than-expected financial results.
benzinga.com Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.
benzinga.com ARS Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ARS Pharmaceuticals (NASDAQ:SPRY) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session. The company's market cap stands at $2.9 million. Capricor Therapeutics (NASDAQ:CAPR) stock moved…
benzinga.com ARS Pharmaceuticals Q2 EPS $(0.63) Misses $(0.48) Estimate, Sales $33.658M Beat $31.321M Estimate ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.48) by 31.25 percent. This is a 36.96 percent decrease over losses…
benzinga.com Can ARS Pharma's New CEO Unlock Neffy's Potential? ARS Pharma (SPRY) co-founder Richard Lowenthal steps down as CEO. President Donn Casale succeeds him amid a strategic shift.
benzinga.com ARS Pharmaceuticals CEO Richard Lowenthal To Depart, Effective July 6; President Donn Casale Named Successor, Effective July 7 ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect against allergic reactions that could lead to…
benzinga.com Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial results. Other big gainers in today's session include FuelCell Energy Inc…
benzinga.com ARS Pharma Reaffirms 2027 Breakeven Goal Despite Missing July Neffy Coverage Wins ARS Pharma reaffirmed its 2027 breakeven target, cut expenses and gained Florida Medicaid access for Neffy despite coverage setbacks.- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday's regular session. The company's market cap stands at $59.4 million. As per the press release, Q1…
benzinga.com Gold Gains Over 1%; Fed's Preferred Inflation Gauge Surges To 3-Year High U.S. stocks traded mostly higher, with the Nasdaq Composite down 0.1%. Industrials jumped 2.5%, while consumer discretionary fell 1.1%. Core PCE rose 3.4% in May.
benzinga.com Leerink Partners Maintains Outperform on ARS Pharmaceuticals, Lowers Price Target to $24 Leerink Partners analyst Roanna Ruiz maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and lowers the price target from $25 to $24.
benzinga.com H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session U.S. stock futures up, Nasdaq 100 futures gain 2%. H.B. Fuller shares dip 8.3% on earnings release and offer to acquire Advanced Medical Solutions.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne…
benzinga.com Why Micron Technology Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket Shares of Micron Technology Inc (NASDAQ: MU) surged in pre-market trading after reporting strong Q3 results and issuing strong guidance. Autozi Internet Technology, Focus Universal, SAGTEC GLOBAL,…
benzinga.com ARS Pharmaceuticals (SPRY) Stock Sinks After-Hours After Commercial Update On Neffy Coverage SPRY stock drops after ARS says no new neffy coverage decisions in July formulary cycle.- benzinga.com 9 Health Care Stocks Moving In Wednesday's After-Market Session Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines…
benzinga.com ARS Pharma Lowers 2026 Cash Operating Expense Guidance To $248M And Reaffirms Path To Cash-Flow Breakeven In 2027 No new commercial formulary additions or coverage decisions issued for neffy (epinephrine nasal spray) in the July 1, 2026 cycle; company to continue payer discussions for potential future…
benzinga.com ARS Pharmaceuticals Continues To Reduce Cash-Based Operating Expenses After No New Commercial Formulary Additions Or Coverage Decisions Have Been Issued For Neffy In The Latest Cycle Access and payer coverage: Despite certain payer discussions ongoing until mid-June, based on recent feedback, no new commercial formulary additions or coverage decisions have been issued for neffy…
benzinga.com Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Raises Price Target to $30 Cantor Fitzgerald analyst Josh Schimmer maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Overweight and raises the price target from $12 to $30.- benzinga.com ARS Pharmaceuticals Q1 2026 Earnings Call Transcript
benzinga.com Earnings Scheduled For May 15, 2026 - benzinga.com ARS Pharmaceuticals Q1 EPS $(0.61) Misses $(0.52) Estimate, Sales $22.681M Beat $22.230M Estimate ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.52) by 17.31 percent. This is a 74.29 percent decrease over losses…
benzinga.com ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) to release first quarter earnings on May 15 before opening bell. Analysts expect a loss of 54 cents per share.
benzinga.com Dow Settles Above 50,000: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone The CNN Business Fear & Greed Index, a measure of market sentiment, improved slightly on Thursday but remains in the Greed zone at 66.1.
benzinga.com Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainers include Kodiak Sciences Inc and Precigen Inc.- benzinga.com Earnings Scheduled For March 9, 2026
benzinga.com What's Going On With Aquestive Therapeutics Stock After FDA Update For Lead Allergic Treatment? Aquestive received an FDA rejection for its allergy film due to safety and use issues. The company plans new studies and targets resubmission in 2026.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session 
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Earnings Scheduled For August 13, 2025
- benzinga.com Earnings Scheduled For May 14, 2025
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - benzinga.com Earnings Scheduled For March 20, 2025
benzinga.com Earnings Scheduled For November 13, 2024